BRP44 anticorps

N° du produit ABIN5564218

Cet anticorps anti-BRP44 Monoclonal Souris (Clone JCM-1) (ABIN5564218) détecte spécifiquement BRP44 dans WB et IP. L’anticorps est réactif avec des échantillons de Humain et Souris.

Aperçu rapide pour BRP44 anticorps (ABIN5564218)

Antigène: BRP44 (Brain Protein 44 (BRP44))

Reactivité: Humain, Souris

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp BRP44 est non-conjugé

Application: Western Blotting (WB), Immunoprecipitation (IP)

Clone: JCM-1

Détail du produit anti-BRP44 anticorps

Specificité: Recognizes endogenous human and mouse MPC-2.

Réactivité croisée: Humain, Souris

Immunogène: Peptide coupled to KLH.

Isotype: IgG2b

Information d'application

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: Lot specific

Buffer: In PBS containing 25 % glycerol and 0.02 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Short Term Storage: +4°C
Long Term Storage: -20°C
Stable for at least 1 year after receipt when stored at -20°C.

Date de péremption: 12 months

Détails sur BRP44

Antigène: BRP44 (Brain Protein 44 (BRP44))

Autre désignation: MPC-2

Sujet: Pyruvate is the end-product of glycolysis, a major substrate for oxidative metabolism, and a branching point for glucose, lactate, fatty acid and amino acid synthesis. The mitochondrial enzymes that metabolize pyruvate are physically separated from cytosolic pyruvate pools and rely on a membrane transport system to shuttle pyruvate across the impermeable inner mitochondrial membrane (IMM). Two proteins, mitochondrial pyruvate carriers MPC-1 and MPC-2, form a heterooligomeric complex in the IMM to facilitate pyruvate transport. This step is required for mitochondrial pyruvate oxidation and carboxylation-critical reactions in intermediary metabolism that are dysregulated in several common metabolic diseases.

Pathways: L'effet Warburg